| Name | Title | Contact Details |
|---|
Issaquah Dental Lab is dedicated to providing a working environment which attracts and retains high quality technicians, staff, and clients. Issaquah Dental Lab's success is defined by an on going commitment to our co-workers, clients, suppliers, and
Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select(TM) offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Start`s NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting.
Synbiotics Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
Nu-Craft Dental Arts is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.